UNCOMMON VARIANTS DETECTED VIA HEREDITARY CANCER PANEL AND SUGGESTIONS FOR GENETIC COUNSELING

[1]  T. D,et al.  The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from circulating cell-free DNA of breast cancer and its effect on protein structure – A computational approach , 2023, Journal of biomolecular structure & dynamics.

[2]  George Priya Doss C,et al.  An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer , 2022, Journal of cellular biochemistry.

[3]  E. Friedman,et al.  Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis , 2022, Breast Cancer Research and Treatment.

[4]  Ceren Alavanda,et al.  Multigene Panel Testing in Turkish Hereditary Cancer Syndrome Patients , 2022, Medeniyet medical journal.

[5]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[6]  A. Camargo,et al.  Monoallelic deleterious MUTYH germline variants as a driver for tumorigenesis , 2021, The Journal of pathology.

[7]  M. Dwyer,et al.  NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  J. Casanova,et al.  The genetic structure of the Turkish population reveals high levels of variation and admixture , 2021, Proceedings of the National Academy of Sciences.

[9]  M. Climent,et al.  Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma , 2021, Genetics in Medicine.

[10]  H. Kajiyama,et al.  Microphthalmia-Associated Transcription Factor-Dependent Melanoma Cell Adhesion Molecule Activation Promotes Peritoneal Metastasis of Ovarian Cancer , 2020, International journal of molecular sciences.

[11]  Reiko Yoshida.  Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis , 2020, Breast Cancer.

[12]  T. van Wezel,et al.  Monoallelic NTHL1 Loss-of-Function Variants and Risk of Polyposis and Colorectal Cancer , 2020, Gastroenterology.

[13]  N. Samadder,et al.  American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. , 2020, Gastrointestinal endoscopy.

[14]  H. Erdem,et al.  Spectrum of BRCA1/BRCA2 variants in 1419 Turkish breast and ovarian cancer patients: a single center study , 2019, Turkish Journal of Biochemistry.

[15]  F. Couch,et al.  A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients , 2019, Genetics in Medicine.

[16]  A. Meindl,et al.  Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer , 2019, Breast Cancer Research.

[17]  C. Markopoulos,et al.  Abstract P4-03-07: Analysis of hereditary cancer syndromes by using a panel of genes: Novel and multiple pathogenic mutations , 2019, Poster Session Abstracts.

[18]  M. Bihoreau,et al.  Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing , 2018, International journal of cancer.

[19]  T. Frebourg,et al.  Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families , 2018, Genetics in Medicine.

[20]  I. Papasotiriou,et al.  Current perspectives on CHEK2 mutations in breast cancer , 2017, Breast cancer.

[21]  P. Goodfellow,et al.  Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer , 2017, JAMA oncology.

[22]  H. Lynch,et al.  Lynch syndrome in the 21st century: clinical perspectives. , 2016, QJM : monthly journal of the Association of Physicians.

[23]  S. Cross,et al.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016, Journal of Medical Genetics.

[24]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[25]  J. Shendure,et al.  A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer , 2015, Nature Genetics.

[26]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[27]  Christopher D. Heinen,et al.  Milestones of Lynch syndrome: 1895–2015 , 2015, Nature Reviews Cancer.

[28]  Randall W Burt,et al.  ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes , 2015, The American Journal of Gastroenterology.

[29]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[30]  David M. Thomas,et al.  Li-Fraumeni syndrome: cancer risk assessment and clinical management , 2014, Nature Reviews Clinical Oncology.

[31]  Rodney J Scott,et al.  Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database , 2013, Nature Genetics.

[32]  Thomas Krausz,et al.  BAP1 and cancer , 2013, Nature Reviews Cancer.

[33]  Aung Ko Win,et al.  Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer , 2011, International journal of cancer.

[34]  M. Genuardi,et al.  Endometrial cancer and somatic G>T KRAS transversion in patients with constitutional MUTYH biallelic mutations. , 2009, Cancer letters.

[35]  H. Campbell,et al.  Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer , 2007, Clinical genetics.

[36]  D. Evans,et al.  Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening , 2007, Journal of Medical Genetics.

[37]  W. Foulkes,et al.  Familial Adenomatous Polyposis , 2006, The American Journal of Gastroenterology.

[38]  G Pellacani,et al.  Attenuated familial adenomatous polyposis and Muir–Torre syndrome linked to compound biallelic constitutional MYH gene mutations , 2005, Clinical genetics.

[39]  K. Offit,et al.  Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Charis Eng,et al.  Highly penetrant hereditary cancer syndromes , 2004, Oncogene.

[41]  L. Lipton,et al.  Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. , 2003, The New England journal of medicine.

[42]  M. Değirmenci,et al.  Genetic Evaluation of Turkish patients with Colorectal Carcinoma in Terms of Lynch Syndrome by Targeted Next Generation Sequencing , 2020, The Journal of Basic and Clinical Health Sciences.

[43]  Dong Liang,et al.  PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS , 2016 .

[44]  M. Yuille,et al.  The ataxia telangiectasia gene in familial and sporadic cancer. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.